Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol in Chronic Pancreatitis
NCT05664880Phase 1Active, not recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jun 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic pancreatitis (CP) comparing Paricalcitol with Placebo (2 arms). Primary endpoint: Feasibility of testing the effect of paricalcitol on health-related quality of life at 12 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
paricalcitol oral solution
03
Conditions
chronic pancreatitis (CP)
Beyond the preview
Go deeper on NCT05664880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664880.